Influenza Vaccination Before Hospital Discharge to Prevent Infections and Heart Problems in Adults Hospitalized for Acute Cardiac Conditions

What this Trial Is About

Patients hospitalized for acute cardiac conditions such as acute myocardial infarction, acute heart failure, pulmonary embolism, arrhythmias, and hypertensive emergencies face a high risk of repeated cardiovascular events. Influenza infection may trigger these adverse cardiac events. Despite evidence supporting influenza vaccination benefits in vulnerable cardiac patients, vaccination rates remain low. This trial explores whether giving the influenza vaccine within 24 hours before hospital discharge can reduce infections, cardiovascular events, and death during the following six months. The study is a randomized, open-label, single-center trial comparing two groups one receiving standard care, including recommendations for influenza vaccination in primary care, and another receiving the influenza vaccine shortly before discharge. The vaccine will be administered prior to leaving the hospital. The research will evaluate safety and effectiveness over a six-month period after hospitalization. Participants will be monitored for infections, unplanned cardiovascular hospitalizations, and cardiovascular deaths during six months post-discharge. Researchers will track these outcomes to assess the impact of pre-discharge vaccination. The total participation period covers six months following hospital discharge, with assessments focusing on health events related to cardiac conditions and influenza infection.

Pre-discharge Influenza Vaccination in Patients Hospitalized for Acute Cardiac Conditions